Y. Deugnier

P. Brissot, D. Guyader, Y. Deugnier, 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Chronic hepatitis C: treat or wait? A prospective study on reasons for treatment or nontreatment in the era of first-generation protease inhibitors

D. Guyader, Y. Deugnier, J. Nousbaum, 2015, European journal of gastroenterology & hepatology.

Iron and hepatocellular carcinoma

Y. Deugnier, B. Turlin, 2001, Journal of gastroenterology and hepatology.

Respective value of alkaline phosphatase, gamma-glutamyl transpeptidase and 5' nucleotidase serum activity in the diagnosis of cholestasis: a prospective study of 80 patients.

P. Brissot, D. Guyader, Y. Deugnier, 2000, Journal of clinical gastroenterology.

Redox active plasma iron in C282Y/C282Y hemochromatosis.

M. Pouchard, Z. Cabantchik, P. Brissot, 2005, Blood.

Redox active plasma iron in C 282 Y / C 282 Y hemochromatosis

M. Pouchard, P. Brissot, O. Loréal, 2005 .

Preneoplastic significance of hepatic iron–free foci in genetic hemochromatosis: A study of 185 patients

P. Brissot, Y. Deugnier, L. Powell, 1993, Hepatology.

Haemochromatosis

Y. Deugnier, L. Powell, L. Powell, 2016, The Lancet.

Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives.

J. L. Le Gall, P. Brissot, R. Moirand, 1999, Gastroenterology.

Gender‐specific phenotypic expression and screening strategies in C282Y‐linked haemochromatosis: a study of 9396 French people

M. Pouchard, J. Mosser, J. L. Le Gall, 2002, British Journal of Haematology.

A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria.

J. L. Le Gall, P. Brissot, R. Moirand, 1999, Journal of hepatology.

Phenotypic expression in detected C282Y homozygous women depends on body mass index.

M. Pouchard, J. Mosser, F. Laine, 2005, Journal of hepatology.

Effects of iron overload on transferrin secretion by cultured fetal rat hepatocytes

G. Lescoat, A. Guillouzo, P. Brissot, 1989, Biology of the cell.

Effect of ornithine on transferrin secretion of rat and human hepatocyte cultures.

G. Lescoat, P. Brissot, B. Desvergne, 2008, Liver.

Iron and neoplasia.

O. Loréal, Y. Deugnier, B. Turlin, 1998, Journal of hepatology.

Magnetic resonance imaging and assessment of liver iron content in genetic hemochromatosis.

C. Jacquelinet, P. Brissot, D. Guyader, 1992, Journal of hepatology.

Hyperferritinemia increases the risk of hyperuricemia in HFE-hereditary hemochromatosis.

G. Coiffier, O. Loréal, Y. Deugnier, 2017, Joint, bone, spine : revue du rhumatisme.

Hereditary hypotransferrinemia can lead to elevated transferrin saturation and, when associated to HFE or HAMP mutations, to iron overload.

P. Brissot, O. Loréal, Y. Deugnier, 2015, Blood cells, molecules & diseases.

Biochemical aspects of alpha-L-fucosidase in hepatocellular carcinoma.

P. Brissot, Y. Deugnier, J. Bretagne, 1989, Hepatology.

Biochemical aspects of α‐L‐fucosidase in hepatocellular carcinoma

P. Brissot, Y. Deugnier, J. Bretagne, 1989 .

Evaluation of computed tomography in the assessment of liver iron overload. A study of 46 cases of idiopathic hemochromatosis.

M. Simon, P. Brissot, M. Bourel, 1989, Gastroenterology.

Dysmetabolic iron overload syndrome (DIOS).

F. Laine, Y. Deugnier, E. Bardou-Jacquet, 2017, Presse medicale.

Clinical Consequences of New Insights in the Pathophysiology of Disorders of Iron and Heme Metabolism.

G. Brittenham, P. Brissot, R. Moirand, 2000, Hematology. American Society of Hematology. Education Program.

Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases

P. Brissot, D. Guyader, A. Guillygomarc’h, 2006, Hepatology.

Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver

P. Brissot, R. Moirand, O. Loréal, 1995, Hepatology.

Sex and acquired cofactors determine phenotypes of ferroportin disease.

D. Vital-Durand, P. Brissot, O. Loréal, 2011, Gastroenterology.

Iron overload disorders.

Y. Deugnier, B. Turlin, 2002, Clinics in liver disease.

Clinical aspects of hemochromatosis.

P. Brissot, R. Moirand, D. Guyader, 2000, Transfusion science.

Decreased iron burden in overweight C282Y homozygous women: Putative role of increased hepcidin production

F. Laine, Y. Deugnier, J. Morcet, 2013, Hepatology.

Chronic liver iron overload in the baboon by ferric nitrilotriacetate

A. Guillouzo, M. Simon, P. Brissot, 1987, Digestive Diseases and Sciences.

Magnetic resonance iron-free nodules in genetic hemochromatosis

P. Brissot, D. Guyader, Y. Gandon, 1999, American Journal of Gastroenterology.

gene discovery: revisiting the diagnostic strategy

P. Brissot, R. Moirand, D. Guyader, 1998 .

Hemochromatosis after the gene discovery: revisiting the diagnostic strategy.

P. Brissot, R. Moirand, D. Guyader, 1998, Journal of hepatology.

Ultrastructural sequences during liver iron overload in genetic hemochromatosis.

P. Brissot, Y. Deugnier, L. Powell, 1997, Journal of hepatology.

A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis.

P. Brissot, R. Moirand, O. Loréal, 1997, The American journal of surgical pathology.

Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemochromatosis.

P. Brissot, R. Moirand, D. Guyader, 1994, Gut.

Differentiation Between Heterozygotes and Homozygotes in Genetic Hemochromatosis by Means of a Histological Hepatic Iron Index: A Study of 192 Cases

P. Brissot, R. Moirand, K. Summers, 1993, Hepatology.

Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations.

C. Jacquelinet, P. Brissot, R. Moirand, 1992, Gastroenterology.

Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients.

G. Lescoat, P. Brissot, R. Moirand, 1992, Journal of hepatology.

Acute infusions of bile salts increase biliary excretion of iron in iron-loaded rats.

A. Favier, P. Brissot, Y. Deugnier, 1991, Gastroenterology.

Increase in glycosylated and nonglycosylated serum ferritin in chronic alcoholism and their evolution during alcohol withdrawal.

G. Lescoat, P. Brissot, R. Moirand, 1991, Alcoholism, clinical and experimental research.

Hepatitis B virus infection markers in genetic haemochromatosis. A study of 272 patients.

C. Jacquelinet, P. Brissot, M. Bourel, 1991, Journal of hepatology.

Iron induction of ferritin synthesis and secretion in human hepatoma cell (Hep G2) cultures.

G. Lescoat, P. Brissot, R. Moirand, 2008, Liver.

Comparative study between biochemical and histological methods and image analysis in liver iron overload.

P. Brissot, M. Bourel, Y. Deugnier, 1982, Journal of clinical pathology.

Ascorbic acid status in idiopathic hemochromatosis.

M. Simon, P. Brissot, M. Bourel, 1978, Digestion.

Early effects of erythropoietin on serum hepcidin and serum iron bioavailability in healthy volunteers

G. Bouguen, O. Loréal, F. Laine, 2011, European Journal of Applied Physiology.

Serum hyaluronate in liver diseases: Study by enzymoimmunological assay

T. Frebourg, B. Delpech, Y. Deugnier, 1986, Hepatology.

Reduced phenotypic expression in genetic hemochromatosis with time: Role of exposure to non-genetic modifiers.

H. Hamdi-Rozé, R. Moirand, D. Guyader, 2019, Journal of hepatology.

Worse Outcomes of Patients With HFE Hemochromatosis With Persistent Increases in Transferrin Saturation During Maintenance Therapy

R. Moirand, D. Guyader, F. Laine, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Increased expression of hepcidin in obese patients: impact on phenotypic expression of hemochromatosis and pathophysiology of dysmetabolic iron overload syndrome.

F. Laine, Y. Deugnier, 2006, Gastroenterology.

Regression of Fibrosis Stage With Treatment Reduces Long-Term Risk of Liver Cancer in Patients With Hemochromatosis Caused by Mutation in HFE.

G. Bouzillé, G. Anderson, F. Laine, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis.

J. Viel, R. Moirand, D. Guyader, 2015, Journal of hepatology.

Carbonyl-iron supplementation induces hepatocyte nuclear changes in BALB/CJ male mice.

P. Brissot, O. Loréal, Y. Deugnier, 1999, Journal of hepatology.

Low penetrant hemochromatosis phenotype in eight families: no evidence of modifiers in the MHC region.

P. Fergelot, J. Mosser, J. L. Le Gall, 2001, Blood cells, molecules & diseases.

Polymorphisms in the HFE Gene

J. L. Le Gall, P. Brissot, R. Moirand, 1999, Human Heredity.

Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment.

P. Brissot, Y. Deugnier, B. Turlin, 1997, Gut.

Circadian variations of transferrin saturation levels in iron‐overloaded patients: implications for the screening of C282Y‐linked haemochromatosis

A. Guillygomarc’h, Y. Deugnier, Jacquelinet Christian, 2003, British journal of haematology.

Is the HLA‐linked haemochromatosis allele implicated in idiopathic refractory sideroblastic anaemia?

M. Krempf, R. Fauchet, B. Grosbois, 1985, British journal of haematology.

Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C.

P. Brissot, D. Guyader, Anne-Sophie Thirouard, 2007, Journal of hepatology.

A simple clinical score to promote and enhance ferroportin disease screening.

X. Causse, B. Drénou, H. Hamdi-Rozé, 2021, Journal of hepatology.

Pathology of Hepatic Iron Overload

Y. Deugnier, B. Turlin, Yves Deugnier1 , 2 , 3, 2011, Seminars in liver disease.

Patient‐reported outcomes and their relation with iron parameters in HFE haemochromatosis during maintenance therapy: A prospective cohort study

F. Laine, Y. Deugnier, J. Morcet, 2022, Liver international : official journal of the International Association for the Study of the Liver.

The iron reabsorption index: a new phenotypic and pathophysiological descriptor in HFE hemochromatosis

R. Moirand, F. Laine, Y. Deugnier, 2013, European journal of gastroenterology & hepatology.

[The diagnosis of hemochromatosis in the era of the gene].

P. Brissot, R. Moirand, D. Guyader, 1999, Annales d'endocrinologie.

Low hepatic iron concentration: evaluation of two complementary methods, colorimetric assay and iron histological scoring.

P. Brissot, J. Delattre, Y. Deugnier, 1999, Journal of clinical pathology.

Variations of hepcidin and iron‐status parameters during the menstrual cycle in healthy women

F. Laine, Y. Deugnier, B. Laviolle, 2016, British journal of haematology.

Assessment of hepatic steatosis: comparison of quantitative and semiquantitative methods in 108 liver biopsies

Bruno Turlin, Fabrice Lainé, D. Purdie, 2009, Liver international : official journal of the International Association for the Study of the Liver.

[Pathology of the umbilical cord].

Y. Deugnier, H. Jouan, D. Beurton, 1983, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

Rare HFE variants are the most frequent cause of hemochromatosis in non‐c282y homozygous patients with hemochromatosis

X. Causse, P. Brissot, H. Hamdi-Rozé, 2016, American journal of hematology.

Tacrolimus diffusion across the peripheral mononuclear blood cell membrane: impact of drug transporters

F. Lemaitre, Y. Deugnier, É. Bellissant, 2018, Fundamental & clinical pharmacology.

Serum α‐L‐Fucosidase: A New Marker for the Diagnosis of Primary Hepatic Carcinoma?

P. Brissot, M. Bourel, Y. Deugnier, 1984 .

Prevalence of the C282Y mutation in Brittany: penetrance of genetic hemochromatosis?

P. Fergelot, J. L. Le Gall, Y. Deugnier, 1998, Annales de genetique.

[Hyperferritinemia not related to hemochromatosis].

P. Brissot, C. Le Lan, Y. Deugnier, 2009, Gastroenterologie clinique et biologique.

Effect of ursodeoxycholic acid on liver iron stores and distribution in rats with normal or iron-supplemented diet.

G. Lescoat, P. Brissot, O. Loréal, 2008, Liver.

A nomogram to predict C282Y hemochromatosis.

S. Chakrabarti, R. Moirand, Y. Deugnier, 2002, The Journal of laboratory and clinical medicine.

Elevated parathyroid hormone 44-68 and osteoarticular changes in patients with genetic hemochromatosis.

P. Brissot, R. Moirand, Y. Deugnier, 1999, Arthritis and rheumatism.

Limitations of Histologic Classification of Iron Overload

Y. Deugnier, B. Turlin, 1998 .

Cell types involved in collagen and fibronectin production in normal and fibrotic human liver

A. Guillouzo, B. Clement, Y. Deugnier, 1986, Hepatology.

Variable age of onset and clinical severity in transferrin receptor 2 related haemochromatosis: novel observations

X. Causse, P. Brissot, S. Cunat, 2013, British journal of haematology.

Pathology of hepatic iron overload.

Y. Deugnier, B. Turlin, 2007, World journal of gastroenterology.

Effects of phlebotomy therapy on cytochrome P450 2e1 activity and oxidative stress markers in dysmetabolic iron overload syndrome: a randomized trial

P. Brissot, A. Guillygomarc’h, F. Laine, 2006, Alimentary pharmacology & therapeutics.

Serumincrease andliver overexpression of carbohydrate 19.9antigen inpatients with genetic haemochromatosis

D. Guyader, Y. Deugnier, E. Boucher, 1994 .

Efficacy and safety of lactosaminated human serum albumin-adenine arabinoside monophosphate in chronic hepatitis B patients non-responders to interferon therapy: a randomised clinical trial.

P. Ambroise‐Thomas, P. Couzigou, P. Marcellin, 2001, Journal of hepatology.

[Sinusoid dilatation and the use of oral contraceptives. Apropos of a case with a review of the literature].

D. Heresbach, P. Brissot, M. Bourel, 1988, Annales de gastroenterologie et d'hepatologie.

[Lipiodolized angiography in hepatocellular carcinomas. Contribution of iodine-131-labelled lipiodol].

Y. Deugnier, J. Raoul, P. Bourguet, 1986, Journal de radiologie.

Liver Adenomatosis With Granulomas in Two Patients on Long-Term Oral Contraceptives

B. le Bail, J. Saric, C. Balabaud, 1992, The American journal of surgical pathology.

A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon.

P. Brissot, D. Guyader, Y. Deugnier, 1999 .

Anomalies du bilan martial

Y. Deugnier, 2013 .

Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing.

P. Brissot, K. Boudjema, R. Moirand, 2002, Journal of hepatology.

Early effects of erythropoietin on serum hepcidin and serum iron bioavailability in healthy volunteers

G. Bouguen, O. Loréal, F. Laine, 2012, European Journal of Applied Physiology.

[Recurrent panniculitis associated with chronic active hepatitis C. Efficacy of Introna (a case)].

Y. Deugnier, F. Le Gall, H. Jouanolle, 1991, Annales de dermatologie et de venereologie.

Comparison of blood tests for liver fibrosis specific or not to NAFLD.

F. Laine, Y. Deugnier, G. Hunault, 2009, Journal of hepatology.

Iron overload of the liver in the baboon. An ultrastructural study.

A. Guillouzo, P. Brissot, M. Bourel, 1985, Journal of hepatology.

Prospective randomized trial of chemoembolization versus intra‐arterial injection of 131I‐labeled–iodized oil in the treatment of hepatocellular carcinoma

D. Guyader, Y. Deugnier, J. Raoul, 1997, Hepatology.

Periodontal pathogens and clinical parameters in chronic periodontitis.

V. Meuric, M. Bonnaure-Mallet, Y. Deugnier, 2019, Molecular oral microbiology.

Bone mineral density in men with genetic hemochromatosis and HFE gene mutation

Y. Rolland, Y. Deugnier, P. Guggenbuhl, 2005, Osteoporosis International.

[Respective value of serum activity of alkaline phosphatase, gamma-glutamyl transpeptidase and 5'-nucleotidase in the diagnosis of intra- and extrahepatic cholestasis].

P. Brissot, D. Guyader, Y. Deugnier, 1997, Gastroentérologie Clinique et Biologique.

Perhexiline maleate toxicity on human liver cell lines.

J. L. Le Gall, A. Guillouzo, M. Bourel, 1980, Gut.

Etude des activites enzymatiques lysosomiques seriques et leucocytaires au cours des hepatopathies chroniquesA study of lysosomal enzyme activities in serum and leukocytes in chronic hepatic disease

Y. Deugnier, 1980 .

[Biological markers in hepatocellular carcinoma].

J. L. Le Gall, Y. Deugnier, M. Blayau, 1988, Annales de biologie clinique.

Short-term prednisolone followed by recombinant human alpha-interferon alone or combined with adenine-arabinoside in chronic hepatitis B. A prospective and randomized trial.

C. Jacquelinet, G. Lescoat, P. Brissot, 1991, Journal of hepatology.

A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload

C. Beaumont, P. Brissot, B. Grandchamp, 2009, Haematologica.

Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging.

Y Gandon, M Carsin, P. Brissot, 1994, Radiology.

Interferon and ursodeoxycholic acid combined therapy in the treatmet of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients

C. Jacquelinet, P. Brissot, R. Moirand, 1995, Hepatology.

Iron and liver cancer.

Y. Deugnier, 2003, Alcohol.

Noninvasive prediction of cirrhosis in C282Y‐linked hemochromatosis

S. Chakrabarti, R. Moirand, D. Guyader, 2002, Hepatology.

Variable expressivity of HJV related hemochromatosis: "Juvenile" hemochromatosis?

H. Hamdi-Rozé, Y. Deugnier, V. David, 2019, Blood cells, molecules & diseases.

A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis

Olivier Loréal, P. Brissot, O. Loréal, 2009, Haematologica.

Modifying factors of the HFE hemochromatosis phenotype

J. Mosser, Y. Deugnier, 2008, Expert review of gastroenterology & hepatology.

Current approach to hemochromatosis.

P. Brissot, O. Loréal, C. Le Lan, 2008, Blood reviews.

Iron and the liver: update 2008.

P. Brissot, O. Loréal, Y. Deugnier, 2008, Journal of hepatology.

Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance.

J. Mosser, P. Brissot, A. Mosser, 2007, American journal of human genetics.

Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.

P. Brissot, M. Cappellini, Y. Deugnier, 2011, Gastroenterology.

Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases.

P. Brissot, D. Guyader, Y. Deugnier, 1993, Gastroenterology.

Genome-wide association study identifies TF as a significant modifier gene of iron metabolism in HFE hemochromatosis.

E. Génin, J. Mosser, C. Férec, 2015, Journal of hepatology.

P0709 : Survival of patients infected by chronic hepatitis c and f0f1 fibrosis at baseline after a 15 years follow-up

R. Moirand, D. Guyader, A. Guillygomarc’h, 2015 .

Increased transferrin saturation is associated with subgingival microbiota dysbiosis and severe periodontitis in genetic haemochromatosis

V. Meuric, M. Bonnaure-Mallet, O. Loréal, 2018, Scientific Reports.

Periodontal status and serum biomarker levels in HFE haemochromatosis patients. A case‐series study

E. Oger, V. Meuric, M. Bonnaure-Mallet, 2017, Journal of clinical periodontology.

Hepatic artery injection of I-131-labeled lipiodol. Part II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases.

Y. Deugnier, J. Raoul, P. Bourguet, 1988, Radiology.

Modulation of albumin secretion by ornithine alpha-ketoglutarate in adult rat hepatocyte cultures and a human hepatoma cell line (HepG2).

G. Lescoat, P. Brissot, M. Bourel, 1989, Annals of nutrition & metabolism.

Both Hepatic and Body Iron Stores Are Increased in Dysmetabolic Iron Overload Syndrome. A Case-Control Study

F. Laine, Y. Deugnier, B. Laviolle, 2015, PloS one.

High vascular endothelial growth factor (VEGF) expression in chemically-induced hepatic microcancers in mice.

P. Brissot, O. Loréal, Y. Deugnier, 2002, Journal of hepatology.

A common SNP near BMP2 is associated with severity of the iron burden in HFE p.C282Y homozygous patients: a follow-up study.

J. Mosser, C. Férec, Y. Deugnier, 2010, Blood cells, molecules & diseases.

A new syndrome of liver iron overload with normal transferrin saturation

Olivier Loréal, P. Brissot, R. Moirand, 1997, The Lancet.

Indicators of iron status are correlated with adiponectin expression in adipose tissue of patients with morbid obesity.

B. Fromenty, F. Bonnet, X. Prieur, 2016, Diabetes & metabolism.

Prevalence of HFE‐related haemochromatosis and secondary causes of hyperferritinaemia and their association with iron overload in 1059 French patients treated by venesection

C. Férec, T. Lefèbvre, Y. Deugnier, 2022, Alimentary pharmacology & therapeutics.

[Alpha-L-fucosidase. A new marker of primary liver cancer?].

P. Brissot, M. Bourel, Y. Deugnier, 1983, Presse medicale.

Malignant melanoma of the hepatic and common bile ducts. A case report and review of the literature.

Y. Deugnier, B. Turlin, B. Launois, 1991, Archives of pathology & laboratory medicine.

Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support.

D. Guyader, Y. Deugnier, J. Raoul, 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Diagnosis of different liver fibrosis characteristics by blood tests in non‐alcoholic fatty liver disease

S. Bertrais, C. Cavaro-Ménard, F. Laine, 2010, Liver international : official journal of the International Association for the Study of the Liver.

Diagnosit value of erythrocyte-free polyamines and histaminemia in malignant hepatic tumors and in liver cirrhosis

P. Brissot, M. Bourel, J. Moulinoux, 1985 .

Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients.

R. Moirand, D. Guyader, A. Guillygomarc’h, 2001, American journal of clinical pathology.

J. Renversez, Y. Deugnier, J. Corberand, 2001, Annales de biologie clinique.

A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C.

M. Ziol, F. Roudot-thoraval, D. Dhumeaux, 1996, Journal of hepatology.

Diagnostic value of erythrocyte-free polyamines and histaminemia in malignant hepatic tumors and in liver cirrhosis.

P. Brissot, M. Bourel, J. Moulinoux, 1985, Clinica chimica acta; international journal of clinical chemistry.

[Hyper-ferritinemia and Gaucher disease].

P. Brissot, R. Moirand, D. Guyader, 1996, Gastroenterologie clinique et biologique.

Pretransplant renal function according to CKD‐EPI cystatin C equation is a prognostic factor of death after liver transplantation

K. Boudjema, D. Guyader, F. Laine, 2016, Liver international : official journal of the International Association for the Study of the Liver.

[766] NON INVASIVE TESTS OF LIVER FIBROSIS IN NAFLD

X. Causse, F. Laine, Y. Deugnier, 2007 .

[Iron overload and HFE gene].

P. Brissot, R. Moirand, D. Guyader, 1999, Gastroenterologie clinique et biologique.

Non‐invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis

P. Brissot, R. Moirand, D. Guyader, 2015, Liver international : official journal of the International Association for the Study of the Liver.

[Indications and results of hepatic transplantation for cancer].

Y. Deugnier, B. Meunier, J. Campion, 1991, Annales de chirurgie.

Histological assessment of liver siderosis.

Y. Deugnier, B. Turlin, 1997, Journal of clinical pathology.

Letters to the Editor: Non-alcoholic steatohepatitis with iron: part of insulin resistanceassociated hepatic iron overload?

P. Brissot, R. Moirand, A. Guillygomarc’h, 2000 .

Non-alcoholic steatohepatitis with iron: part of insulin resistance-associated hepatic iron overload?

P. Brissot, R. Moirand, A. Guillygomarc’h, 2000, Journal of hepatology.

GNPAT Variant associated with severe iron overload in HFE hemochromatosis

J. Mosser, Y. Deugnier, M. de Tayrac, 2015, Hepatology.

Iron absorption in nonalcoholic steatohepatitis and dysmetabolic iron overload syndrome

F. Laine, Y. Deugnier, M. Ruivard, 2015, Hepatology.

Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD

S. Bertrais, C. Cavaro-Ménard, F. Laine, 2011, European journal of gastroenterology & hepatology.

EASL POSTGRADUATE COURSE METABOLIC LIVER DISEASE EVERYTHING YOU NEED FOR THE INTERNATIONAL LIVER CONGRESSTM ON YOUR SMARTPHONE !

Y. Deugnier, S. Francque, 2015 .

Reduction of liver iron content following tratment of chronic hepatitis C

P. Brissot, R. Moirand, Y. Deugnier, 1995 .

A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon

P. Brissot, D. Guyader, Y. Deugnier, 1999, American Journal of Gastroenterology.

Do genetic variations in antioxidant enzymes influence the course of hereditary hemochromatosis?

D. Pessayre, P. Nahon, A. Sutton, 2011, Antioxidants & redox signaling.

Semi-Quantitative Assessment of Hemosiderin Distribution Accurately Reflects Reductions in Liver Iron Concentration Following Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine in Patients with Transfusion-Dependent Anemia.

J. Ford, H. Cario, E. Vichinsky, 2005 .

Evaluation and interpretation of iron in the liver.

Y. Deugnier, B. Turlin, 1998, Seminars in diagnostic pathology.

[Histochemical detection of hepatic iron. A comparative study of four stains].

P. Brissot, R. Moirand, O. Loréal, 1992, Annales de pathologie.

Ferroportin Diseases: Functional Studies, a Link Between Genetic and Clinical Phenotype

P. Brissot, O. Loréal, A. Mosser, 2013, Human mutation.

Prospective randomized trial of chemoembolization versus intra‐arterial injection of 131I‐labeled–iodized oil in the treatment of hepatocellular carcinoma

D. Guyader, Y. Deugnier, J. Raoul, 1997, Hepatology.

Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption

P. Brissot, R. Moirand, D. Guyader, 2004, Hepatology.

Importance of the functional sensitivity determination of a serum hyaluronic acid assay for the prediction of liver fibrosis in patients with features of the metabolic syndrome

F. Laine, Y. Deugnier, C. Massart, 2006, Clinical chemistry and laboratory medicine.

The Pathology of Hepatic Iron Overload

Y. Deugnier, B. Turlin, 2012 .

HFE mutations in insulin resistance-associated hepatic iron overload.

R. Moirand, A. Guillygomarc’h, Y. Deugnier, 2000, Journal of hepatology.

Reply to: "Reduced mortality due to phlebotomy in moderately iron-loaded HFE Haemochromatosis? The need for clinical trials".

F. Laine, Y. Deugnier, E. Bardou-Jacquet, 2015, Journal of hepatology.

Serum alpha-L-fucosidase: a new marker for the diagnosis of primary hepatic carcinoma?

P. Brissot, M. Bourel, Y. Deugnier, 1984, Hepatology.

H. Hamdi-Rozé, Y. Deugnier, V. David, 2018 .

Haemochromatosis

Y. Deugnier, L. Powell, Rebecca C Seckington, 2016, The Lancet.

The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis

P. Brissot, R. Moirand, Y. Deugnier, 1997, Hepatology.

Differentiation Between Heterozygotes and Homozygotes in Genetic Hemochromatosis by Means of a Histological Hepatic Iron Index: A Study of 192 Cases

P. Brissot, R. Moirand, K. Summers, 1993, Hepatology.

Pretransplant renal function according to CKD‐EPI cystatin C equation is a prognostic factor of death after liver transplantation

K. Boudjema, D. Guyader, F. Laine, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Steatosis, iron and HFE genes

D. Guyader, Y. Deugnier, 2008 .

HFE based re-evaluation of heterozygous hemochromatosis.

J. L. Le Gall, P. Brissot, R. Moirand, 2002, American journal of medical genetics.

Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis.

J. Viel, R. Moirand, D. Guyader, 2015, Journal of hepatology.

[Dysmetabolic iron overload syndrome: a systemic disease?].

F. Laine, Y. Deugnier, 2014, Presse medicale.

GNPAT Variant associated with severe iron overload in HFE hemochromatosis

J. Mosser, Y. Deugnier, M. de Tayrac, 2015, Hepatology.

Long-term course after initial iron removal of iron excess in patients with dysmetabolic iron overload syndrome

D. Guyader, F. Laine, Y. Deugnier, 2014, European journal of gastroenterology & hepatology.